ASCO Annual Meeting: Gynecologic Cancer | Conference

ERBB2/ERBB3+ Uterine Cancer Shows Disease Control With Combination of Pertuzumab and Trastuzumab
June 07, 2021

Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers.

Advanced Cervical Cancer Shows No Survival Benefit With Adjuvant Chemotherapy
June 04, 2021

Awaited outcomes of the phase 3 OUTBACK trial presented at the 2021 ASCO Annual Meeting do not indicate benefit of adjuvant chemotherapy for patients with cervical cancer.

Molecular-Based Classification for Endometrial Cancer Could Help Predict Survival
June 23, 2016

Researchers were able to molecularly classify endometrial cancers with distinct survival differences using a new classification tool called ProMisE that uses clinically applicable methods.